[{"id":"413fd329-dd85-45a6-b07c-a0fee98c2f35","acronym":"","url":"https://clinicaltrials.gov/study/NCT04743661","created_at":"2021-02-08T13:52:25.106Z","updated_at":"2024-07-02T16:35:12.204Z","phase":"Phase 2","brief_title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","source_id_and_acronym":"NCT04743661","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/04/2022","start_date":" 04/04/2022","primary_txt":" Primary completion: 10/30/2029","primary_completion_date":" 10/30/2029","study_txt":" Completion: 10/30/2030","study_completion_date":" 10/30/2030","last_update_posted":"2024-03-29"},{"id":"3e16b0ef-4807-4c66-8af1-db2894850add","acronym":"","url":"https://clinicaltrials.gov/study/NCT05064306","created_at":"2021-10-01T11:54:31.866Z","updated_at":"2024-07-02T16:35:13.448Z","phase":"","brief_title":"131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults","source_id_and_acronym":"NCT05064306","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Omblastys (131I-omburtamab)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-21"}]